Latest News

  • Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review Read More
  • Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting Read More
  • Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET Read More
  • Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Response to Current Events

Response to Current Events
Response to Current Events Read Our Statement